Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease

被引:276
作者
Johnson, RJ
Kivlighn, SD
Kim, YG
Suga, S
Fogo, AB
机构
[1] Univ Washington, Med Ctr, Div Nephrol, Seattle, WA 98195 USA
[2] Merck & Co Inc, West Point, PA USA
[3] Vanderbilt Univ, Dept Pathol, Nashville, TN USA
基金
美国国家卫生研究院;
关键词
gouty nephropathy; hypertension; uric acid; tubulointerstitial disease;
D O I
10.1016/S0272-6386(99)70295-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
An elevated uric acid level is associated with cardiovascular disease. Hyperuricemia is predictive for the development of both hypertension and coronary artery disease; it is increased in patients with hypertension, and, when present in hypertension, an elevated uric acid level is associated with increased cardiovascular morbidity and mortality. Serum uric acid level should be measured in patients at risk for coronary artery disease because it carries prognostic information. Hyperuricemia is caused by decreased renal excretion. In this article, we suggest that this may be mediated by intrarenal ischemia with lactate generation and the inhibition of the secretion of urate by the anion exchange transport system. The possibility that hyperuricemia directly contributes to cardiovascular or renal disease needs to be reconsidered. Although hyperuricemia is associated with a number of cardiovascular or renal risk factors, several studies have found uric acid level to be independently associated with increased mortality by multivariate analysis. If hyperuricemia is directly toxic, the most likely site is the kidney. Chronic hyperuricemia is strongly associated with chronic tubulointerstitial disease, and many of these patients have decreased renal function. Although it is possible that the hyperuricemia could simply be the consequence of the renal disease, further studies are necessary to rule out a pathogenic role for uric acid in the development of renal disease and salt-dependent hypertension. (C) 1999 by the National Kidney Foundation, Inc.
引用
收藏
页码:225 / 234
页数:10
相关论文
共 82 条
[1]
GOUT AND CORONARY HEART-DISEASE - THE FRAMINGHAM-STUDY [J].
ABBOTT, RD ;
BRAND, FN ;
KANNEL, WB ;
CASTELLI, WP .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1988, 41 (03) :237-242
[2]
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[3]
THE ROLE OF LEAD IN GOUT NEPHROPATHY [J].
BATUMAN, V ;
MAESAKA, JK ;
HADDAD, B ;
TEPPER, E ;
LANDY, E ;
WEDEEN, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (09) :520-523
[4]
REQUIEM FOR GOUTY NEPHROPATHY [J].
BECK, LH ;
HARRINGTON, JT ;
KASSIRER, JP ;
PERRONE, R ;
MADIAS, NE ;
STROM, J ;
KURTIN, P ;
CANZANELLO, V .
KIDNEY INTERNATIONAL, 1986, 30 (02) :280-287
[5]
BENGTSSON C, 1988, ACTA MED SCAND, V224, P549
[6]
Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy [J].
Bennett, WM ;
DeMattos, A ;
Meyer, MM ;
Andoh, T ;
Barry, JM .
KIDNEY INTERNATIONAL, 1996, 50 (04) :1089-1100
[7]
RENAL-FUNCTION IN GOUT .4. ANALYSIS OF 524 GOUTY SUBJECTS INCLUDING LONG-TERM FOLLOW-UP STUDIES [J].
BERGER, L ;
YU, TF .
AMERICAN JOURNAL OF MEDICINE, 1975, 59 (05) :605-613
[8]
Bohle A, 1996, KIDNEY INT, V49, pS2
[9]
HYPERURICEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE - THE FRAMINGHAM-STUDY [J].
BRAND, FN ;
MCGEE, DL ;
KANNEL, WB ;
STOKES, J ;
CASTELLI, WP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 121 (01) :11-18
[10]
BRECKENRIDGE A, 1966, LANCET, V1, P15